Screener
AbbVie ABBV Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Net revenues by Product | ||||||
| Botox Cosmetic | $728M+5.2% | $668M+20.1% | $717M+4.4% | $637M-5.1% | $692M-5.1% | |
| Botox Therapeutic | $1.04B+12.3% | $1.01B+16.5% | $990M+13.4% | $985M+16.2% | $928M+14.0% | |
| Elahere | $211M+32.7% | $198M+10.6% | $182M+23.0% | $170M+22.3% | $159M+24.2% | |
| Humira | $756M-35.9% | $688M-38.6% | $1.25B-25.9% | $993M-55.4% | $1.18B-58.1% | |
| Juvederm Collection | $245M-5.8% | $232M+0.4% | $249M-10.8% | $253M-1.9% | $260M-24.2% | |
| Mavyret | $295M-21.3% | $351M+14.7% | $324M+11.3% | $312M+3.3% | $375M+1.6% | |
| Other Aesthetics | $309M-5.5% | $286M-9.2% | $320M-3.6% | $303M-2.3% | $327M+2.8% | |
| Other Neuroscience | $117M+113% | $125M-19.4% | $47M-16.1% | $46M-17.9% | $55M-11.3% | |
| Qulipta | $350M+31.1% | $296M+53.4% | $288M+43.3% | $288M+63.6% | $267M+78.0% | |
| Rinvoq | $2.53B+24.5% | $2.12B+23.3% | $2.37B+29.4% | $2.18B+35.3% | $2.03B+41.8% | |
| Skyrizi | $5.51B+24.5% | $4.48B+30.9% | $5.01B+32.5% | $4.71B+46.9% | $4.42B+62.2% | |
| Ubrelvy | $392M+16.0% | $339M+41.3% | $339M+11.9% | $354M+31.6% | $338M+46.3% | |
| Venclexta | $771M+11.6% | $770M+15.8% | $710M+8.4% | $726M+7.2% | $691M+8.5% | |
| Vraylar | $1.07B+19.0% | $905M+18.3% | $1.02B+10.6% | $934M+6.7% | $900M+16.3% | |
| Vyalev | $256M+161% | $201M+219% | $183M+316% | $138M+393% | $98M+444% |
FAQ
- How does AbbVie break its business down?
- AbbVie (ABBV) reports net revenues by product across 19 parts — All other, Botox Cosmetic, Botox Therapeutic, Elahere and Epkinly. Each is extracted from the segment footnotes and tracked over time.
- Where does AbbVie's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in AbbVie's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
